Thomas Blaettler

744 total citations
13 papers, 374 citations indexed

About

Thomas Blaettler is a scholar working on Psychiatry and Mental health, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Thomas Blaettler has authored 13 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Psychiatry and Mental health, 4 papers in Molecular Biology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Thomas Blaettler's work include Schizophrenia research and treatment (4 papers), Tryptophan and brain disorders (3 papers) and Receptor Mechanisms and Signaling (3 papers). Thomas Blaettler is often cited by papers focused on Schizophrenia research and treatment (4 papers), Tryptophan and brain disorders (3 papers) and Receptor Mechanisms and Signaling (3 papers). Thomas Blaettler collaborates with scholars based in Switzerland, United Kingdom and United States. Thomas Blaettler's co-authors include Dragana Bugarski‐Kirola, George Garibaldi, Carol Reid, Stephen R. Marder, Rodrigo A. Bressan, Henry A. Nasrallah, Celso Arango, Mark R. Dixon, Samuele Tosatti and Julie Napieralski and has published in prestigious journals such as Langmuir, Biological Psychiatry and British Journal of Pharmacology.

In The Last Decade

Thomas Blaettler

13 papers receiving 370 citations

Peers

Thomas Blaettler

PMH

CMN

PHARM

Daniel Elswick United States

Anna Braun Germany

Paul J. Markovitz United States

Shadreck Mzengeza Canada

Richard D. Kaplan United States

Abigail I. Nash United States

M. Wang United States

Jean-Marie Launay France

Maureen Fay-McCarthy United States

Alexandre Duarte Gigante Brazil

Daniel Elswick United States

Thomas Blaettler

114 ×0.9

65 ×0.5

PMH

106 ×1.0

CMN

60 ×0.8

36 ×0.7

PHARM

Citations per year, relative to Thomas Blaettler Thomas Blaettler (= 1×) peers Daniel Elswick

Countries citing papers authored by Thomas Blaettler

Since Specialization

Citations

This map shows the geographic impact of Thomas Blaettler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Blaettler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Blaettler more than expected).

Fields of papers citing papers by Thomas Blaettler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Blaettler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Blaettler. The network helps show where Thomas Blaettler may publish in the future.

Co-authorship network of co-authors of Thomas Blaettler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Blaettler. A scholar is included among the top collaborators of Thomas Blaettler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Blaettler. Thomas Blaettler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Erickson, Craig A., Laura Pérez‐Cano, Ernest V. Pedapati, et al.. (2024). Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines. 12(7). 1430–1430. 1 indexed citations

Dimachkie, Mazen M., Pedro Machado, Thomas Blaettler, et al.. (2021). The Early History of Arimoclomol for Inclusion Body Myositis. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 2(2). 1 indexed citations

Bugarski‐Kirola, Dragana, Thomas Blaettler, Celso Arango, et al.. (2016). Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies. Biological Psychiatry. 82(1). 8–16. 109 indexed citations

Bugarski‐Kirola, Dragana, Nakao Iwata, Carol Reid, et al.. (2016). Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. The Lancet Psychiatry. 3(12). 1115–1128. 76 indexed citations

Blaettler, Thomas, Janice Smith, Jillian Smith, et al.. (2016). P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease. Alzheimer s & Dementia. 12(7S_Part_12). 12 indexed citations

Smith, Janice, et al.. (2016). O4‐05‐05: Free and Cued Selective Reminding Test as an Inclusion Criterion for Early Alzheimer's Disease Clinical Trial Populations. Alzheimer s & Dementia. 12(7S_Part_7). 1 indexed citations

Schooler, Nina R., Robert W. Buchanan, Thomas Laughren, et al.. (2015). Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. Schizophrenia Research. 162(1-3). 169–174. 27 indexed citations

Edgar, Chris J., et al.. (2014). Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Research. 218(1-2). 219–224. 26 indexed citations

Feuerbach, Dominik, Nicole Pezous, H. Weiss, et al.. (2014). AQW051, a novel, potent and selectiveα7 nicotinicAChreceptor partial agonist: pharmacological characterization and phaseIevaluation. British Journal of Pharmacology. 172(5). 1292–1304. 27 indexed citations

10.

Blaettler, Thomas, Dragana Bugarski‐Kirola, W. Wolfgang Fleischhacker, et al.. (2014). Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study. Schizophrenia Research. 158(1-3). e2–e3. 11 indexed citations

11.

Bugarski‐Kirola, Dragana, Celso Arango, W. Wolfgang Fleischhacker, et al.. (2014). EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME. Schizophrenia Research. 153. S20–S20. 5 indexed citations

12.

Stoeck, Katharina, Lorenz Amsler, Thomas Blaettler, et al.. (2009). A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001–2004. BMC Public Health. 9(1). 18–18. 24 indexed citations

13.

Jaehne, Evelin, et al.. (2006). Carboxy-Terminated Oligo(ethylene glycol)−Alkane Phosphate: Synthesis and Self-Assembly on Titanium Oxide Surfaces. Langmuir. 23(2). 377–381. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact